My Sanford Chart allows you secure online access to your personal health information and your child's health information. It's available anywhere you have internet access. There is no cost to you and registering is quick and simple.

Sign Up for My Sanford Chart
Study ID: CTSU S1115
Title:

Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in Patients with Metastatic Pancreatic Cancer after Prior Chemotherapy

Description:

The purpose of this study is to find out what effects, good and/or bad, the combination of MK-2206 and AZD6244 hydrogen sulfate or a standard combination of oxaliplatin and fluorouracil (5-FU) called mFOLFOX, has on metastatic pancreatic cancer. MK-2206 and AZD6244 hydrogen sulfate are investigational drugs that have not been approved by the FDA for use in this type of cancer. Participants in this study have pancreatic cancer that has spread and has worsened after one treatment.

Location:
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Principal Investigator:
Miroslaw Mazurczak MD,Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Disease:
Pancreas
Stage:
Phase II

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list